This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Autoimmune disease				
Systemic lupus erythematosus (SLE)	Solute carrier family 15 member 4 (SLC15A4; PHT1)	<p>Mouse studies suggest antagonizing SLC15A4 could help treat SLE. In a mouse model for SLE, a loss-of-function mutation in <i>Slc15a4</i> prolonged survival and decreased type I interferon and autoimmune antibody production compared with what was seen in mice with wild-type <i>Slc15a4</i>. Next steps include developing a high throughput assay for inhibitors of SLC15A4 or its interaction with endosomal toll-like receptors (TLRs), which are thought to mediate the effects of SLC15A4 activity.</p> <p>SciBX 6(8); doi:10.1038/scibx.2013.184 Published online Feb. 28, 2013</p>	Patent pending; licensed to an undisclosed company	<p>Baccala, R. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Feb. 4, 2013; doi:10.1073/pnas.1222798110 Contact: Argyrios N. Theofilopoulos, The Scripps Research Institute, La Jolla, Calif. e-mail: argyrio@scripps.edu Contact: Roberto Baccala, same affiliation as above e-mail: rbaccala@scripps.edu Contact: Bruce Beutler, The University of Texas Southwestern Medical Center, Dallas, Texas e-mail: bruce.beutler@utsouthwestern.edu</p>